Valuation: RAPT Therapeutics, Inc.

Market Cap 94Cr 83Cr 77Cr 70Cr 132.76Cr 8.91TCr 134.89Cr 929.5Cr 364.44Cr 4.65TCr 352.24Cr 344.75Cr 15TCr P/E 2023
-8.16x
P/E 2024 -0.5x
Enterprise Value 71Cr 63Cr 59Cr 53Cr 100.71Cr 6.76TCr 102.33Cr 705.12Cr 276.46Cr 3.53TCr 267.22Cr 261.53Cr 11TCr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
96.87%
Yield 2023 *
-
Yield 2024 -
1 day+0.07%
Current year+71.30%
Current year 29.77
Extreme 29.77
58.02
1 year 25.5
Extreme 25.5001
58.02
3 years 5.67
Extreme 5.6652
218.8
5 years 5.67
Extreme 5.6652
325.92
10 years 5.67
Extreme 5.6652
409.68
Manager TitleAgeSince
President - 03/03/2026
Treasurer - 03/03/2026
Director TitleAgeSince
Director/Board Member - 03/03/2026
Director/Board Member - 03/03/2026
Date Insider Type Main position Quantity % Market Cap. Importance
03/03/26 Tender

Chief Technology Officer

1,64,742 0.5945%
03/03/26 Tender

Chief Financial Officer

2,05,703 0.7423%
03/03/26 Tender

Director

59,858 0.2160%
Change 5-day change 1-year change 3-year change Capi.($)
+0.07%-.--%+97.75%-40.70% 179.41Cr
-6.60%-8.56%+49.38%+63.51% 6.5TCr
+0.03%+5.56%+9.10%+69.05% 5.12TCr
-4.09%-0.11%+2.22%+53.15% 5.12TCr
-1.53%+2.70%+30.48%+34.12% 4.39TCr
-1.34%+4.12%+16.64%+115.13% 4.2TCr
-5.97%-6.22%+228.95%+454.22% 3.81TCr
+6.53%+8.02%+16.40%+53.41% 3.32TCr
-0.90%-10.49%+37.09%-3.70% 2.52TCr
-1.07%+2.33%+19.43%+9.98% 2.25TCr
Average -1.49%-0.30%+50.74%+80.82% 3.74TCr
Weighted average by Cap. -2.19%-0.50%+44.50%+95.88%

Financials

2023 2024
Net sales - -
Net income -12Cr -10Cr -9.62Cr -8.76Cr -17Cr -1.11TCr -17Cr -115.67Cr -45Cr -578.46Cr -44Cr -43Cr -1.84TCr -13Cr -12Cr -11Cr -9.73Cr -18Cr -1.23TCr -19Cr -128.61Cr -50Cr -643.17Cr -49Cr -48Cr -2.05TCr
Net Debt -15Cr -14Cr -13Cr -11Cr -21Cr -1.44TCr -22Cr -150.49Cr -59Cr -752.58Cr -57Cr -56Cr -2.4TCr -23Cr -20Cr -19Cr -17Cr -32Cr -2.15TCr -33Cr -224.37Cr -88Cr -1.12TCr -85Cr -83Cr -3.58TCr
Projected Income Statement - Annual - RAPT Therapeutics, Inc.
Logo RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Employees
60
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RAPT Stock